ArticleHuman mutation2026
Multimodal Analysis Reveals Immune Suppression Associated With Hepatocellular Carcinoma Related to RBM27 and Constructs a Prognostic Model.
Article in Human mutation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Hepatocellular carcinoma (HCC) exhibits aggressive progression and therapy resistance due to immunosuppressive microenvironments. RNA-binding motif protein 27 (RBM27) is implicated in RNA processing, yet its role in HCC immune evasion remains uncharacterized. Methods: Multiomics analyses (TCGA/GEO, single-cell/spatial transcriptomics) were integrated with functional validation (in vitro/vivo). RBM27 expression was assessed in HCC tissues/cell lines. Knockdown models (lentiviral shRNA) evaluated impacts on proliferation, migration, invasion (Transwell/wound healing), and tumor growth (xenografts). Immune profiling (ssGSEA/TIP), metabolic pathways (GSEA/KEGG), and prognostic modeling (Cox/nomogram) were performed. Spatial transcriptomics mapped immune niche alterations. Results: Compared with adjacent nontumor tissues, the expression level of RBM27 was markedly overexpressed in HCC tissues. Genomic analysis revealed that this upregulation is driven by copy number variations (CNVs), particularly gene amplification, alongside specific mutational patterns. This abnormal upregulation was closely correlated with advanced clinical stages of the disease, elevated AFP, and poor survival (OS/DSS/PFI; Conclusion: Driven by genetic alterations including gene amplification, RBM27 promotes HCC progression by remodeling an immunosuppressive microenvironment via OXPHOS activation, acting as a biomarker for diagnosis and prognosis along with a potential therapeutic target, it could assist in combating immune escape.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.